Table 1.
Patient demographics and baseline characteristics
| N = 24 | |
|---|---|
| Median age, years (range) | 57.5 (39–72) |
| Male/female sex [n (%)] | 8/16 (33/67) |
| Race [n (%)] | |
| Caucasian | 23 (96) |
| Black or African American | 1 (4) |
| ECOG performance status [n (%)] | |
| 0 | 7 (29) |
| 1 | 17 (71) |
| Mean weight, kg (SD) | 69.5 (18.9) |
| Weight range, kg | 43–101 |
| Mean BSA, m2 (SD) | 1.8 (0.3) |
| BSA range, m2 | 1.4–2.2 |
| Cancer type [n (%)] | |
| Colorectal | 6 (25) |
| Cervical | 4 (17) |
| Melanoma | 2 (8) |
| NSCLC | 2 (8) |
| Ovarian | 2 (8) |
| Pancreatic | 2 (8) |
| Othera | 6 (25) |
| ≥3 prior lines of therapy [n (%)] | 18 (75) |
| Most frequent prior systemic therapies [n (%)] | |
| Carboplatin | 10 (42) |
| Paclitaxel | 10 (42) |
| Bevacizumab | 9 (38) |
BSA body surface area, ECOG Eastern Cooperative Oncology group, NSCLC non-small cell lung cancer, SD standard deviation
aAdrenal, breast, prostate, leiomyosarcoma, small cell lung cancer, and peritoneal carcinoma (n = 1 each)